MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Qi, Wenqing ^a   Cooke, Larry S ^a   Stejskal, Amy ^a   Riley, Christopher ^a   Della Croce, Kimiko ^a   Saldanha, Jose W ^b   Bearss, David ^c   Mahadevan, Daruka ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c SuperGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; IMATINIB; MP 470; PROTEIN KINASE B; PROTEIN P85; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; MP470; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOTOXICITY; DOWNSTREAM PROCESSING; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; ANIMAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MOUSE MUTANT; MULTIGENE FAMILY; PHOSPHORYLATION; PROSTATE TUMOR; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICE; MICE, SCID; MULTIGENE FAMILY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 66749185251     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-142     Document Type: Article

References (51)

1. Jemal A Siegel R Ward E Murray T Xu J Thun MJ Cancer statistics, 2007 CA Cancer J Clin 2007, 57(1):43-66. 17237035
2. Pinthus JH Pacik D Ramon J Diagnosis of prostate cancer Recent Results Cancer Res 2007, 175:83-99. 17432555
3. Pomerantz M Kantoff P Advances in the treatment of prostate cancer Annu Rev Med 2007, 58:205-220. 16987081
4. Chang SS Management of high risk metastatic prostate cancer: Defining risk at the time of initial treatment failure J Urol 2006, 176(6 Pt 2):S57-60. 17084169
5. Loblaw DA Virgo KS Nam R Somerfield MR Ben-Josef E Mendelson DS Middleton R Sharp SA Smith TJ Talcott J et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 2007, 25(12):1596-1605. 17404365
6. Mercader M Sengupta S Bodner BK Manecke RG Cosar EF Moser MT Ballman KV Wojcik EM Kwon ED Early effects of pharmacological androgen deprivation in human prostate cancer BJU Int 2007, 99(1):60-67. 17227493
7. Wagner M Garzotto M Lemmon D Eilers KM Beer TM Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer Urology 2005, 65(4):799. 15833548
8. Tannock IF de Wit R Berry WR Horti J Pluzanska A Chi KN Oudard S Theodore C James ND Turesson I et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004, 351(15):1502-1512. 15470213
9. Sowery RD So AI Gleave ME Therapeutic options in advanced prostate cancer: Present and future Curr Urol Rep 2007, 8(1):53-59. 17239317
10. Shawver LK Slamon D Ullrich A Smart drugs: Tyrosine kinase inhibitors in cancer therapy Cancer Cell 2002, 1(2):117-123. 12086869
11. Krause DS Van Etten RA Tyrosine kinases as targets for cancer therapy N Engl J Med 2005, 353(2):172-187. 16014887
12. Hochhaus A Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) Ann Hematol 2004, 83(Suppl 1):S65-66. 15124676
13. de Jager J Stebbing J Erlotinib or capecitabine with gemcitabine in pancreatic cancer? Future Oncol 2006, 2(2):161-163. 16563084
14. Pawson T Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems Cell 2004, 116(2):191-203. 14744431
15. Schlessinger J Cell signaling by receptor tyrosine kinases Cell 2000, 103(2):211-225. 11057895
16. Hofer MD Fecko A Shen R Setlur SR Pienta KG Tomlins SA Chinnaiyan AM Rubin MA Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors Neoplasia 2004, 6(5):503-512. 1531653 15548358
17. Robinson D He F Pretlow T Kung HJ A tyrosine kinase profile of prostate carcinoma Proc Natl Acad Sci USA 1996, 93(12):5958-5962. 39170 8650201
18. Singh D Febbo PG Ross K Jackson DG Manola J Ladd C Tamayo P Renshaw AA D'Amico AV Richie JP et al. Gene expression correlates of clinical prostate cancer behavior Cancer Cell 2002, 1(2):203-209. 12086878
19. El Sheikh SS Domin J Abel P Stamp G Lalani el N Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF Neoplasia 2004, 6(6):846-853. 1531689 15720812
20. Majumder PK Sellers WR Akt-regulated pathways in prostate cancer Oncogene 2005, 24(50):7465-7474. 16288293
21. Ghosh PM Malik SN Bedolla RG Wang Y Mikhailova M Prihoda TJ Troyer DA Kreisberg JI Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocr Relat Cancer 2005, 12(1):119-134. 15788644
22. Lin J Adam RM Santiestevan E Freeman MR The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells Cancer Res 1999, 59(12):2891-2897. 10383151
23. Liao Y Grobholz R Abel U Trojan L Michel MS Angel P Mayer D Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer Int J Cancer 2003, 107(4):676-680. 14520710
24. Graff JR Konicek BW McNulty AM Wang Z Houck K Allen S Paul JD Hbaiu A Goode RG Sandusky GE et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression J Biol Chem 2000, 275(32):24500-24505. 10827191
25. Kreisberg JI Malik SN Prihoda TJ Bedolla RG Troyer DA Kreisberg S Ghosh PM Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer Cancer Res 2004, 64(15):5232-5236. 15289328
26. Le Page C Koumakpayi IH Alam-Fahmy M Mes-Masson AM Saad F Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients Br J Cancer 2006, 94(12):1906-1912. 16721361
27. Litman P Ohne O Ben-Yaakov S Shemesh-Darvish L Yechezkel T Salitra Y Rubnov S Cohen I Senderowitz H Kidron D et al. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway Biochemistry 2007, 46(16):4716-4724. 17397140
28. Li B Sun A Youn H Hong Y Terranova PF Thrasher JB Xu P Spencer D Conditional Akt activation promotes androgen-independent progression of prostate cancer Carcinogenesis 2007, 28(3):572-583. 17032658
29. Pienta KJ Bradley D Mechanisms underlying the development of androgen-independent prostate cancer Clin Cancer Res 2006, 12(6):1665-1671. 16551847
30. Murillo H Huang H Schmidt LJ Smith DI Tindall DJ Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state Endocrinology 2001, 142(11):4795-4805. 11606446
31. Lu S Ren C Liu Y Epner DE PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells Int J Oncol 2006, 28(1):245-251. 16328002
32. Pfeil K Eder IE Putz T Ramoner R Culig Z Ueberall F Bartsch G Klocker H Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells Prostate 2004, 58(3):259-268. 14743465
33. Qi W Martinez JD Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation Radiat Res 2003, 160(2):217-223. 12859233
34. Horoszewicz JS Leong SS Kawinski E Karr JP Rosenthal H Chu TM Mirand EA Murphy GP LNCaP model of human prostatic carcinoma Cancer Res 1983, 43(4):1809-1818. 6831420
35. Kubler HR van Randenborgh H Treiber U Wutzler S Battistel C Lehmer A Wagenpfeil S Hartung R Paul R In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines Prostate 2005, 63(4):385-394. 15617027
36. Secrist JP Burns LA Karnitz L Koretzky GA Abraham RT Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events J Biol Chem 1993, 268(8):5886-5893. 8383678
37. Hsieh AC Moasser MM Targeting HER proteins in cancer therapy and the role of the non-target HER3 Br J Cancer 2007, 97(4):453-457. 17667926
38. Aziz MH Nihal M Fu VX Jarrard DF Ahmad N Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins Mol Cancer Ther 2006, 5(5):1335-1341. 16731767
39. Yang Y Ikezoe T Takeuchi T Adachi Y Ohtsuki Y Koeffler HP Taguchi H Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways Oncol Rep 2006, 15(6):1581-1590. 16685399
40. Nelson EC Evans CP Mack PC Devere-White RW Lara PN Jr Inhibition of Akt pathways in the treatment of prostate cancer Prostate Cancer Prostatic Dis 2007, 10(4):331-339. 17471291
41. Gioeli D Signal transduction in prostate cancer progression Clin Sci (Lond) 2005, 108(4):293-308. 15603554
42. Grasso AW Wen D Miller CM Rhim JS Pretlow TG Kung HJ ErbB kinases and NDF signaling in human prostate cancer cells Oncogene 1997, 15(22):2705-2716. 9400997
43. Koumakpayi IH Diallo JS Le Page C Lessard L Gleave M Begin LR Mes-Masson AM Saad F Expression and nuclear localization of ErbB3 in prostate cancer Clin Cancer Res 2006, 12(9):2730-2737. 16675564
44. Munster PN Marchion DC Basso AD Rosen N Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway Cancer Res 2002, 62(11):3132-3137. 12036925
45. Kominsky SL Hobeika AC Lake FA Torres BA Johnson HM Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells Cancer Res 2000, 60(14):3904-3908. 10919667
46. Nasu K Tanji N Nishioka R Wang J Yanagihara Y Ozawa A Yokoyama M Sakayama K EXpression of ErbB proteins in human prostate Arch Androl 2006, 52(3):185-190. 16574600
47. Ratan HL Gescher A Steward WP Mellon JK ErbB receptors: Possible therapeutic targets in prostate cancer? BJU Int 2003, 92(9):890-895. 14632841
48. Normanno N Campiglio M De LA Somenzi G Maiello M Ciardiello F Gianni L Salomon DS Menard S Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann Oncol 2002, 13(1):65-72. 11863114
49. Arteaga CL HER3 and mutant EGFR meet MET Nat Med 2007. 13(6):675-677. 17554333
50. Engelman JA Zejnullahu K Mitsudomi T Song Y Hyland C Park JO Lindeman N Gale CM Zhao X Christensen J et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 2007, 316:5827-1039. 1043 17463250
51. Mahadevan D Cooke L Riley C Swart R Simons B Della Croce K Wisner L Iorio M Shakalya K Garewal H et al A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors Oncogene 2007, 26(27):3909-3919. 17325667